CD74-ROS1 · CHIMERIC PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13CD74-ROS1 shows approved-linked disease relevance led by cancer. 3 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P04233. Start with cancer, then reuse UniProt P04233 as the stable protein anchor across project notes and exports.
Start with cancer, then reuse UniProt P04233 as the stable protein anchor across project notes and exports.
CD74-ROS1 shows approved-linked disease relevance led by cancer. 3 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with cancer because it currently carries approved-linked support. Linked drugs include REPOTRECTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyHLA class II histocompatibility antigen gamma chain
Review this target as CD74-ROS1, mapped to UniProt P04233. ChEMBL maps the protein component as HLA class II histocompatibility antigen gamma chain. Sequence length is 296 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats CD74-ROS1 as ChEMBL target CHEMBL4680046, mapped to UniProt P04233. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether CD74-ROS1 is the right protein anchor across sources, using UniProt P04233 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why cancer is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | CD74-ROS1 |
| Target Type | CHIMERIC PROTEIN |
| Organism | Homo sapiens |
| UniProt | P04233 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | HLA class II histocompatibility antigen gamma chain |
| UniProt Accession | P04233 |
| Component Type | Protein |
| Sequence Length | 296 aa |
HLA class II histocompatibility antigen gamma chain
Review this target as CD74-ROS1, mapped to UniProt P04233. ChEMBL maps the protein component as HLA class II histocompatibility antigen gamma chain. Sequence length is 296 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
CD74-ROS1 shows approved-linked disease relevance led by cancer. 3 more disease programs remain visible in the same review block.
Start review with cancer because it currently carries approved-linked support. Linked drugs include REPOTRECTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3286830 | 9.64 | IC50 | 0.23 | Approved |
| CHEMBL601719 | 8.41 | IC50 | 3.9 | Approved |
| CHEMBL3545311 | 7.75 | IC50 | 18.0 | Approved |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 3 | 3 | 8.3 |